Skip to main content
Premium Trial:

Request an Annual Quote

Beckman, Recognizing Inverness' Bid for Biosite, Extends Own Offer Deadline

NEW YORK (GenomeWeb News) — Beckman Coulter today said it has extended its offer to buy Biosite to May 2, which the day that a counteroffer by Inverness Medical Innovations runs out.
 
Late last week, Biosite told Beckman Coulter that it “currently intends” to accept a rival offer from Inverness, which proposes to buy the company for $90 a share. Beckman’s original offer, made in March, was for $85 a share.
 
Beckman now has until May 2 to make Biosite a better offer. If Biosite chooses Inverness, it would have to pay Beckman an agreed-upon $50 million termination fee, which Inverness has said it would cover.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.